Tags

Type your tag names separated by a space and hit enter

Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza.
Chem Rev. 2009 Sep; 109(9):4398-438.CR

Links

Publisher Full Text

Authors+Show Affiliations

Magano J
Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340, USA. Javier.Magano@Pfizer.com

MeSH

Antiviral AgentsEnzyme InhibitorsHumansInfluenza, HumanNeuraminidaseOseltamivirZanamivir

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19537777

Citation

Magano, Javier. "Synthetic Approaches to the Neuraminidase Inhibitors Zanamivir (Relenza) and Oseltamivir Phosphate (Tamiflu) for the Treatment of Influenza." Chemical Reviews, vol. 109, no. 9, 2009, pp. 4398-438.
Magano J. Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza. Chem Rev. 2009;109(9):4398-438.
Magano, J. (2009). Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza. Chemical Reviews, 109(9), 4398-438. https://doi.org/10.1021/cr800449m
Magano J. Synthetic Approaches to the Neuraminidase Inhibitors Zanamivir (Relenza) and Oseltamivir Phosphate (Tamiflu) for the Treatment of Influenza. Chem Rev. 2009;109(9):4398-438. PubMed PMID: 19537777.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza. A1 - Magano,Javier, PY - 2009/6/23/entrez PY - 2009/6/23/pubmed PY - 2009/11/13/medline SP - 4398 EP - 438 JF - Chemical reviews JO - Chem Rev VL - 109 IS - 9 SN - 1520-6890 UR - https://www.unboundmedicine.com/medline/citation/19537777/Synthetic_approaches_to_the_neuraminidase_inhibitors_zanamivir__Relenza__and_oseltamivir_phosphate__Tamiflu__for_the_treatment_of_influenza_ L2 - https://doi.org/10.1021/cr800449m DB - PRIME DP - Unbound Medicine ER -